Composition for reducing uric acid and application thereof

Abstract

The invention relates to a uric acid reducing composition and application thereof, and belongs to the technical field of health care products. The uric acid reducing composition disclosed by the invention is prepared from the following components in parts by mass: 4 to 6 parts of sour cherry concentrated powder, 1 to 3 parts of chrysanthemum flower powder, 2 to 4 parts of radix asparagi powder, 1 to 3 parts of herba cepbalanoplosis segeti powder, 1 to 3 parts of vitamin C and 0.5 to 1.5 parts of compound bacterium powder, wherein the total viable count of the compound bacterium powder is 20 billion CFU / g, the compound bacterium powder is composed of TSP05 and TSR332 with the viable count ratio being 1: (1.3-2), the TSP05 is lactobacillus plantarum with the preservation number being CGMCC No.16710, and the TSR332 is lactobacillus reuteri with the preservation number being CGMCC No.15528. The invention further discloses a preparation method of the compound bacterium powder. The uric acid reducing composition has the remarkable effects of reducing uric acid, protecting the liver and kidney and reducing the activity of xanthine oxidase.

Description

Technical Field

[0001] This invention relates to the field of health product technology, and in particular to a uric acid-lowering composition and its application. Background Technology

[0002] With the prevalence of high-purine diets and metabolic syndrome, the global prevalence of hyperuricemia continues to rise. As the end product of purine metabolism, excessive accumulation of uric acid can lead to various complications such as gout, chronic kidney disease, and cardiovascular disease.

[0003] Hyperuricemia is mainly caused by two factors: increased uric acid production and decreased uric acid excretion, or both simultaneously. Therefore, clinically, hyperuricemia is classified into three types: excessive production, impaired excretion, and mixed types. Current clinical treatments primarily rely on xanthine oxidase inhibitors (such as allopurinol and febuxostat) and uricosuric drugs (benzbromarone). However, these drugs have side effects such as liver and kidney toxicity and allergic reactions, and long-term use can easily lead to drug resistance. Furthermore, they cannot completely improve or cure hyperuricemia. Therefore, there is an urgent need to develop natural, non-toxic, side-effect-free, and comprehensively effective products to prevent and treat hyperuricemia. Summary of the Invention

[0004] The purpose of this invention is to overcome the shortcomings of the prior art and provide a uric acid-lowering composition and its application.

[0005] To achieve the above objectives, the technical solution adopted by the present invention is as follows: In a first aspect, the present invention provides a uric acid-lowering composition comprising the following components in parts by weight: Sour cherry concentrate: 4-6 parts; Chrysanthemum powder: 1-3 parts; Asparagus powder: 2-4 parts; Small thistle powder: 1-3 parts; Vitamin C: 1-3 servings; Compound microbial powder: 0.5-1.5 parts; The total viable bacteria count of the compound bacterial powder is 20 billion CFU / g; The compound bacterial powder is composed of TSP05 and TSR332 with a live bacteria ratio of 1:1.3-2; TSP05 is Lactobacillus plantarum, with accession number CGMCC No. 16710; TSR332 is Lactobacillus reuteri, with accession number CGMCC No. 15528.

[0006] By selecting specific component ratios, the present invention yields a uric acid-lowering composition that significantly reduces uric acid levels in the blood and has a significant inhibitory effect on xanthine oxidase activity in the blood.

[0007] In a preferred embodiment of the uric acid-lowering composition of the present invention, the uric acid-lowering composition comprises the following components in parts by weight: Sour cherry concentrate: 5 servings; Chrysanthemum powder: 2 parts; Asparagus powder: 3 parts; Small thistle powder: 2 portions; Vitamin C: 2 servings; Compound bacterial powder: 1 part; The total viable bacteria count of the compound bacterial powder is 20 billion CFU / g; The compound bacterial powder is composed of TSP05 and TSR332 with a live bacteria ratio of 1:1.7; TSP05 is Lactobacillus plantarum, with accession number CGMCC No. 16710; TSR332 is Lactobacillus reuteri, with accession number CGMCC No. 15528.

[0008] Under preferred conditions, the uric acid-lowering composition of the present invention has the technical effect of better inhibiting xanthine oxidase activity and reducing the level of uric acid in the blood.

[0009] Secondly, the present invention provides the use of the uric acid-lowering composition described in the first aspect in the preparation of health products or pharmaceuticals with uric acid-lowering effects.

[0010] As a preferred embodiment of the application described in this invention, the dosage form of the health product or medicine includes tablets, capsules, pills, powders, or oral liquids.

[0011] Thirdly, the present invention provides a powder with uric acid-lowering effects, the powder comprising the uric acid-lowering composition described in the first aspect.

[0012] As a preferred embodiment of the uric acid-lowering powder of the present invention, the powder further includes a sweetener.

[0013] Fourthly, the present invention provides an oral liquid with uric acid-lowering effects, the oral liquid comprising the uric acid-lowering composition described in the first aspect.

[0014] As a preferred embodiment of the oral liquid with uric acid-lowering effect described in this invention, the oral liquid also includes sweeteners, preservatives, and drinking water.

[0015] Compared with the prior art, the beneficial effects of the present invention are as follows: This invention discloses a uric acid-lowering composition comprising specific mass fractions of six components: concentrated sour cherry powder, chrysanthemum powder, asparagus powder, thistle powder, vitamin C, and compound bacterial powder. These six components work synergistically to lower blood uric acid levels. The concentrated sour cherry powder is rich in anthocyanins and flavonoids, which can inhibit the activity of xanthine oxidase in the liver. Simultaneously, the concentrated sour cherry powder can also inhibit inflammatory factors (such as IL-6 and TNF-α) in the body, helping to alleviate symptoms such as joint redness, swelling, heat, and pain during acute gout attacks. Chrysanthemum powder can reduce uric acid reabsorption and increase its excretion in urine and feces by regulating the expression of renal urate transport proteins (such as URAT1 and GLUT9) and intestinal transport proteins (such as ABCG2). Meanwhile, its main active ingredient, flavonoids, can also inhibit xanthine oxidase and block uric acid production. The flavonoids in asparagus powder and thistle powder can reduce uric acid production by inhibiting xanthine oxidase activity, and promote uric acid excretion by regulating renal transport proteins through the diuretic effect of asparagus powder and thistle powder. In addition, it can also improve the abnormal renal function indicators caused by hyperuricemia, thereby assisting in the regulation of uric acid content in the body at multiple stages. The present invention uses the above-mentioned plant powders and compound bacterial powder together to synergistically enhance the inhibitory effect of the composition on xanthine oxidase activity, thereby reducing the uric acid level in the serum and improving the abnormal renal function caused by hyperuricemia. In addition, the composition is relatively stable and can be stored for a long time when formulated with excipients into powder or oral liquid. Attached Figure Description

[0016] Figure 1 These are pathological sections of the kidneys of mice in the normal control group.

[0017] Figure 2 The images show pathological sections of the kidneys of mice in the model control group.

[0018] Figure 3 The images show pathological sections of the kidneys of mice in the positive control group.

[0019] Figure 4 The image shows a pathological section of mouse kidney from composition 1.

[0020] Figure 5 The image shows a pathological section of mouse kidney from composition 2.

[0021] Figure 6 The image shows a pathological section of mouse kidney from composition 3. Detailed Implementation

[0022] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Unless otherwise specified, specific conditions in the embodiments are performed under conventional conditions or conditions recommended by the manufacturer. Unless otherwise specified, the components of the formulations in the embodiments are all conventional commercially available products. The following embodiments are further illustrations of the present invention, but not limitations thereof.

[0023] The raw materials used in this invention and their sources are as follows: Sour cherry concentrate was purchased from Iprona Lana SpA, lot number: 2501304662; Chrysanthemum powder was purchased from ORYZA OIL & FAT CHEMICAL, item number: B-508; Asparagus powder was purchased from Gedison, item number: GDS20; The small thistle powder was purchased from Snowt, item number: SNT200506; Vitamin C was purchased from Sigma-Aldrich, product number: A5960; TSP05 is *Lactobacillus plantarum*, with accession number CGMCC No. 16710, and a viable count of 2 × 10⁻⁶. 10 CFU / g; TSR332 is *Lactobacillus reuteri*, with accession number CGMCC No. 15528, and a viable count of 2 × 10⁻⁶. 10 CFU / g; TSF331 is a fermenting lactic acid bacterium with the accession number CGMCC No. 15527 and a viable count of 2 × 10⁻⁶. 10 CFU / g.

[0024] Unless otherwise specified, the reagents, methods and equipment used in this invention are all conventional reagents, methods and equipment in the field; and unless otherwise specified, the raw materials used in parallel experiments are from the same batch.

[0025] Preparation of uric acid-lowering compositions Composition 1 Composed of the following components by mass: Sour cherry concentrate: 5 servings; Chrysanthemum powder: 2 parts; Asparagus powder: 3 parts; Small thistle powder: 2 portions; Vitamin C: 2 servings; Compound bacterial powder: 1 part; The total viable bacteria count of the compound bacterial powder is 20 billion CFU / g; The compound bacterial powder is composed of TSP05 and TSR332 with a live bacteria ratio of 1:1.7; TSP05 is Lactobacillus plantarum, with accession number CGMCC No. 16710; TSR332 is Lactobacillus reuteri, with accession number CGMCC No. 15528.

[0026] Preparation method: Accurately weigh the above components and mix them evenly. Seal and store in the dark.

[0027] Composition 2 Composed of the following components by mass: Sour cherry concentrate: 4 servings; Chrysanthemum powder: 1 part; Asparagus powder: 2 portions; Small thistle powder: 1 portion; Vitamin C: 1 serving; Compound microbial powder: 0.5 parts; The total viable bacteria count of the compound bacterial powder is 20 billion CFU / g; The compound bacterial powder is composed of TSP05 and TSR332 with a live bacteria ratio of 1:2. TSP05 is Lactobacillus plantarum, with accession number CGMCC No. 16710; TSR332 is Lactobacillus reuteri, with accession number CGMCC No. 15528.

[0028] The preparation method is the same as that of composition 1.

[0029] Composition 3 Composed of the following components by mass: Sour cherry concentrate: 6 servings; Chrysanthemum powder: 3 parts; Asparagus powder: 4 portions; Small thistle powder: 3 portions; Vitamin C: 3 servings; Compound microbial powder: 1.5 parts; The total viable bacteria count of the compound bacterial powder is 20 billion CFU / g; The compound bacterial powder is composed of TSP05 and TSR332 with a live bacteria ratio of 1:1.3; TSP05 is Lactobacillus plantarum, with accession number CGMCC No. 16710; TSR332 is Lactobacillus reuteri, with accession number CGMCC No. 15528.

[0030] The preparation method is the same as that of composition 1.

[0031] Composition ①: Unlike composition 1, it lacks sour cherry concentrate powder. The missing mass is made up by chrysanthemum powder, asparagus powder and thistle powder in a mass ratio of 2:3:2. The remaining components, mass parts and preparation methods are the same as composition 1.

[0032] Composition ②: Unlike composition 1, it lacks chrysanthemum powder. The missing mass is made up by sour cherry concentrate, asparagus powder and thistle powder in a mass ratio of 5:3:2. The remaining components, mass parts and preparation methods are the same as those of composition 1.

[0033] Composition ③: Unlike composition 1, it lacks asparagus powder. The missing mass is made up by sour cherry concentrate, chrysanthemum powder and thistle powder in a mass ratio of 5:2:2. The remaining components, mass parts and preparation methods are the same as those of composition 1.

[0034] Composition ④: Unlike composition 1, it lacks thistle powder. The missing mass fraction is made up by sour cherry concentrate, chrysanthemum powder and asparagus powder in a mass ratio of 5:2:3. The remaining components, mass fractions and preparation methods are the same as composition 1.

[0035] Composition ⑤: Unlike composition 1, the compound bacterial powder lacks TSP05. The missing number of live bacteria is made up with TSR332 and the total number of live bacteria in the compound bacterial powder remains unchanged. The remaining components, mass fractions and preparation methods are the same as those of composition 1.

[0036] Composition ⑥: Unlike Composition 1, the compound bacterial powder lacks TSR332. The missing number of live bacteria is made up with TSP05 and the total number of live bacteria in the compound bacterial powder remains unchanged. The remaining components, mass parts and preparation methods are the same as Composition 1.

[0037] Composition ⑦: Unlike Composition 1, the compound bacterial powder uses TSF331 and other live bacteria to replace TSR332, and the total number of live bacteria in the compound bacterial powder remains unchanged. The remaining components, mass parts and preparation methods are the same as those of Composition 1.

[0038] Composition ⑧: Unlike Composition 1, the compound bacterial powder uses TSF331 and other live bacteria to replace TSP05, and the total number of live bacteria in the compound bacterial powder remains unchanged. The remaining components, mass parts and preparation methods are the same as those of Composition 1.

[0039] Composition 9: Unlike composition 1, the compound microbial powder is composed of TSP05, TSR332 and TSF331 with a live bacteria ratio of 1:1:1, and the total live bacteria count of the compound microbial powder is 20 billion CFU / g. The remaining components, mass parts and preparation methods are the same as those of composition 1.

[0040] Composition ⑩: Unlike composition 1, the compound bacterial powder is composed of TSP05 and TSR332 with a live bacteria ratio of 2:1, and the total live bacteria count of the compound bacterial powder is 20 billion CFU / g. The remaining components, mass fractions and preparation methods are the same as those of composition 1.

[0041] Composition Unlike Composition 1, this composition lacks concentrated sour cherry powder, chrysanthemum powder, thistle powder, and asparagus powder. The missing components are made up by a compound microbial powder, wherein the total viable count of the compound microbial powder is 20 billion CFU / g. The compound microbial powder consists of TSP05 and TSR332 with a viable count ratio of 1:1.3. TSP05 is Lactobacillus plantarum, with the preservation number CGMCC No. 16710; TSR332 is Lactobacillus reuteri, with the preservation number CGMCC No. 15528. The remaining components, components by weight, and preparation methods are the same as those in Composition 1.

[0042] Composition Unlike composition 1, this composition lacks compound bacterial powder. The missing mass fraction is made up by a mass ratio of 5:2:3:2 of concentrated sour cherry powder, chrysanthemum powder, asparagus powder, and thistle powder. The remaining components, mass fractions, and preparation methods are the same as those of composition 1.

[0043] Test Example 1: Toxicological Testing of the Composition Wild-type AB strain zebrafish, 5 days post-fertilization (5 Dpf), were selected for the experiment. They were randomly assigned to groups and transferred to 6-well plates (30 fish per well, 3 mL / well). A normal control group, a model control group, and an experimental group were set up. Except for the normal control group, all other groups were given 10 mmol / L potassium oxonate and 500 μmol / L sodium xanthine to establish a zebrafish hyperuricemia model. After the model was established, the experimental group was given the test samples (test samples and concentrations are shown in Table 1). After treatment at 28℃ for 24 h, the safety of the test samples was determined.

[0044] Table 1. Test samples, concentrations, and zebrafish mortality rates

[0045] Based on Table 1, no mortality was observed in zebrafish at a concentration of 800 μg / mL, indicating that the composition is highly safe at this concentration.

[0046] Test Example 2: Effect of the Composition on Uric Acid Levels Wild-type AB strain zebrafish were selected 5 days post-fertilization (5 Dpf). They were randomly assigned to groups and transferred to 6-well plates (30 fish per well, 3 mL / well). A normal control group, a model control group, a positive control group, and an experimental group were established. Except for the normal control group, all other groups were given 10 mmol / L potassium oxonate and 500 μmol / L sodium xanthine to establish a zebrafish hyperuricemia model. After the model was established, the positive control group was given 200 μg / mL benzbromarone, and the experimental group was given the test sample (test samples and concentrations are shown in Table 2).

[0047] After being treated at 28 ℃ for 24 h, the normal control group, model control group, positive control group, and experimental group of zebrafish were washed three times with standard dilution water (containing 294.0 mg / L calcium chloride dihydrate, 123.3 mg / L magnesium sulfate heptahydrate, 63.0 mg / L sodium bicarbonate, and 5.5 mg / L potassium chloride). The uric acid levels of the zebrafish were analyzed using a uric acid reagent kit (batch number: 20250912, Nanjing Jiancheng Biotechnology Institute, China). Statistical results are expressed as mean ± SE and statistical analysis was performed. p < 0.05 indicated statistical significance.

[0048] Table 2 Effects of the composition on uric acid levels Group Test sample Concentration (μg / mL) Uric acid content (μmol / gprot, mean±SE) normal control group - - <![CDATA[9.763±0.490 * ]]> Model control group - - 15.017±0.054 Positive control group Benzbromarone 200 <![CDATA[10.926±0.086 * ]]> Experimental group 1 Composition 1 500 <![CDATA[11.643±0.132 * ]]> Experimental group 2 Composition 2 500 <![CDATA[11.852±0.085 * ]]> Experimental group 3 Composition 3 500 <![CDATA[12.319±0.075 * ]]> Experimental group ① Composition ① 500 <![CDATA[13.671±0.236 *# ]]> Experimental group ② Composition ② 500 <![CDATA[13.945±0.114 *# ]]> Experimental group ③ Composition ③ 500 <![CDATA[13.752±0.236 *# ]]> Experimental group ④ Composition ④ 500 <![CDATA[13.707±0.180 *# ]]> Experimental group ⑤ Composition ⑤ 500 <![CDATA[13.529±0.174 *# ]]> Experimental group ⑥ Composition ⑥ 500 <![CDATA[13.734±0.215 *# ]]> Experimental group ⑦ Composition ⑦ 500 <![CDATA[14.265±0.142 *# ]]> Experimental group ⑧ Composition ⑧ 500 <![CDATA[13.957±0.157 *# ]]> Experimental group 9 Composition 9 500 <![CDATA[13.162±0.201 *# ]]> Experimental group 10 Composition ⑩ 500 <![CDATA[14.072±0.133 *# ]]> Note: "*" indicates p < 0.05 compared with the model control group; "#" indicates p < 0.05 compared with composition 1.

[0049] As shown in Table 2, the uric acid levels in the model control group and the normal control group were significantly different (p < 0.001), indicating that the model was successfully established.

[0050] Comparing the results of experimental groups 1-3 with the model control group, it can be seen that the composition described in this invention has a certain effect on reducing uric acid levels in the zebrafish model with high uric acid, and the effect is significant (p<0.001). Comparing the results of composition 1 with compositions ①-④, it can be seen that there is a significant synergistic effect between the concentrated sour cherry powder, chrysanthemum powder, asparagus powder, thistle powder, compound bacterial powder, and vitamin C in the composition. The combined use can significantly reduce the uric acid level in the zebrafish model with high uric acid. Comparing the results of composition 1 with compositions ⑤-⑩, it can be seen that the compound bacterial powder composed of different bacteria has different effects. The compound bacterial powder obtained by combining TSP05 with accession number CGMCC No.16710 and TSR332 with accession number CGMCC No.15528 in a specific mass ratio as specified in this invention, when used together with concentrated sour cherry powder, chrysanthemum powder, asparagus powder, thistle powder, and vitamin C, has a synergistic effect and can significantly reduce the uric acid level in the zebrafish model with high uric acid.

[0051] Test Example 3: Effect of the Composition on Xanthine Oxidase Activity The xanthine oxidase activity of zebrafish in each group of test example 2 was detected using a xanthine oxidase kit (batch number: A073250725, Shanghai Beyotime Biotechnology Co., Ltd., China). Statistical results are expressed as mean ± SE and statistical analysis was performed. p < 0.05 indicated that the difference was statistically significant.

[0052] Table 3 Effect of the composition on xanthine oxidase activity Group Test sample Concentration (μg / mL) Xanthine oxidase activity (mU / mgprot, mean±SE) normal control group - - <![CDATA[0.248±0.002 * ]]> Model control group - - 0.354±0.003 Positive control group Benzbromarone 200 <![CDATA[0.255±0.002 * ]]> Experimental group 1 Composition 1 500 <![CDATA[0.261±0.001 * ]]> Experimental group 2 Composition 2 500 <![CDATA[0.268±0.004 * ]]> Experimental group 3 Composition 3 500 <![CDATA[0.272±0.001 * ]]> Experimental group ① Composition ① 500 <![CDATA[0.287±0.005 *# ]]> Experimental group ② Composition ② 500 <![CDATA[0.305±0.002 *# ]]> Experimental group ③ Composition ③ 500 <![CDATA[0.292±0.001 *# ]]> Experimental group ④ Composition ④ 500 <![CDATA[0.289±0.007 *# ]]> Experimental group ⑤ Composition ⑤ 500 <![CDATA[0.284±0.003 *# ]]> Experimental group ⑥ Composition ⑥ 500 <![CDATA[0.293±0.004 *# ]]> Experimental group ⑦ Composition ⑦ 500 <![CDATA[0.325±0.002 *# ]]> Experimental group ⑧ Composition ⑧ 500 <![CDATA[0.313±0.003 *# ]]> Experimental group 9 Composition 9 500 <![CDATA[0.277±0.002 *# ]]> Experimental group 10 Composition ⑩ 500 <![CDATA[0.309±0.006 *# ]]> Note: "*" indicates p < 0.05 compared with the model control group; "#" indicates p < 0.05 compared with composition 1.

[0053] As shown in Table 3, the xanthine oxidase activity in the model control group and the normal control group in this invention showed significant changes (p < 0.001), indicating that the model was successfully established.

[0054] Comparing the results of compositions 1-3 with the model control group, it can be seen that the compositions described in this invention have a certain reducing effect on xanthine oxidase activity in the zebrafish model with high uric acid, and the effect is significant (p<0.001). Comparing the results of composition 1 with compositions ①-④, it can be seen that there is a significant synergistic effect between the concentrated sour cherry powder, chrysanthemum powder, asparagus powder, thistle powder, compound bacterial powder, and vitamin C in the composition. The combined use can significantly reduce the xanthine oxidase activity in the zebrafish model with high uric acid. Comparing the results of composition 1 with compositions ⑤-⑩, it can be seen that the compound bacterial powder composed of different bacteria has different effects. The compound bacterial powder obtained by combining TSP05 with accession number CGMCC No.16710 and TSR332 with accession number CGMCC No.15528 in a specific mass ratio as specified in this invention, when used together with concentrated sour cherry powder, chrysanthemum powder, asparagus powder, thistle powder, and vitamin C, has a synergistic effect and can significantly reduce the xanthine oxidase activity in the zebrafish model with high uric acid.

[0055] Test Example 4: Effect of the composition on serum uric acid, blood urea nitrogen, and creatinine levels in a mouse model of hyperuricemia. Modeling: A mouse model of hyperuricemia induced by potassium oxonate injection was selected for the experiment. Eight groups were set up: a normal control group, a model control group (potassium oxonate injection), a positive control group (hyperuricemia model + febuxostat), and an experimental group (hyperuricemia model + test sample), with six mice in each group. Modeling and drug administration were carried out according to the groupings in Table 4.

[0056] Table 4. Mouse model grouping

[0057] After drug administration, 300 μL of blood was collected without anticoagulation, centrifuged to obtain serum, and stored at -80°C. Kidneys were harvested and fixed with paraformaldehyde. Serum uric acid, blood urea nitrogen, and creatinine levels were evaluated; kidney pathological analysis was performed; and XOD and ADA activities in the kidneys were assessed.

[0058] The results of serum uric acid, blood urea nitrogen, and creatinine are shown in Table 5.

[0059] Table 5. Effects of the composition on serum uric acid, creatinine, and urea nitrogen levels in mice.

[0060] Note: "*" indicates p < 0.05 compared with the model control group; "#" indicates p < 0.05 compared with composition 1.

[0061] The XOD and ADA activities in the kidneys are shown in Table 6.

[0062] Table 6. Effects of the composition on XOD and ADA activities in mouse kidneys.

[0063] Note: "*" indicates p < 0.05 compared with the model control group; "#" indicates p < 0.05 compared with composition 1.

[0064] The results, as shown in Tables 5 and 6, indicated that compared with the normal control group, the model group mice showed significantly increased serum uric acid (UA), creatinine (CRE), and blood urea nitrogen (BUN) levels, as well as significantly increased renal XOD and ADA activities (P < 0.05), demonstrating that potassium oxonate successfully induced hyperuricemia in mice. Compared with the model group, the febuxostat positive drug group showed a decreasing trend in serum UA, CRE, and BUN levels, as well as renal XOD and ADA activities, which were statistically significant (P < 0.05).

[0065] In the experimental group, comparing compositions 1-3 with the model control group, it was found that after using the compositions, the levels of uric acid, creatinine, and urea nitrogen in the mouse serum, as well as the activities of XOD and ADA in the kidneys, all decreased to a certain extent, and the decrease was statistically significant (P < 0.05), indicating that the compositions have certain biological activity in alleviating hyperuricemia in mice. Comparing composition 1 with compositions 11 and 12, it was found that there is a significant synergistic effect among the concentrated sour cherry powder, chrysanthemum powder, asparagus powder, small thistle powder, vitamin C, and compound bacterial powder in this invention. When the above raw materials are used together, they can synergistically enhance the effect and further alleviate hyperuricemia in mice.

[0066] Preparation of powders with uric acid-lowering effects Powder 1 Composed of the following components by mass: Composition 1: 4 parts; Sweetener: 0.5 parts; The sweetener mentioned above is white sugar; Preparation method of powder 1: Mix the above ingredients evenly, package, and store in the dark.

[0067] Preparation of oral solutions with uric acid-lowering effects Oral liquid 1 Composed of the following components by mass percentage: Composition 1: 6wt% Sweetener: 1 wt% Preservative: 0.002 wt%; Drinking water replenished to 100 wt%; The sweetener is white sugar; the preservative is potassium sorbate. Preparation method of oral liquid 1: A1: Mix the sweetener, preservative and 1 / 2 drinking water evenly to obtain mixture 1; A2: Mix composition 1 with the remaining drinking water until homogeneous to obtain mixture 2; A3: Mix mixture 2 and mixture 1 evenly to obtain oral liquid, fill, seal and store away from light.

[0068] Test Example 5: Stability Test of Powders or Oral Liquids The obtained powder 1 and oral liquid 1 were stored at 37℃ in the dark for 30 days, 60 days, and 90 days, and the appearance, color, and state of powder 1 and oral liquid 1 were observed. The results are shown in Table 7.

[0069] Table 7 Stability Tests for Powders or Oral Liquids Group 30 days 60 days 90 days Powder 1 No clumping, no discoloration, and the state is basically the same as the initial state. No clumping, no discoloration, and the state is basically the same as the initial state. No clumping, no discoloration, and the state is basically the same as the initial state. Oral liquid 1 It is clear, without discoloration or odor, and its state is basically the same as its initial state. It is clear, without discoloration or odor, and its state is basically the same as its initial state. It is clear, without discoloration or odor, and its state is basically the same as its initial state. As shown in Table 7, after 90 days of storage at 37°C, the appearance, color, and state of the powder or oral liquid did not change significantly; this indicates that the powder or oral liquid prepared by the present invention is stable and has a long shelf life.

[0070] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A uric acid-lowering composition, characterized in that, Includes the following components by weight: Sour cherry concentrate: 4-6 parts; Chrysanthemum powder: 1-3 parts; Asparagus powder: 2-4 parts; Small thistle powder: 1-3 parts; Vitamin C: 1-3 servings; Compound microbial powder: 0.5-1.5 parts; The total viable bacteria count of the compound bacterial powder is 20 billion CFU / g; The compound bacterial powder is composed of TSP05 and TSR332 with a live bacteria ratio of 1:1.3-2; TSP05 is Lactobacillus plantarum, with accession number CGMCC No. 16710; TSR332 is Lactobacillus reuteri, with accession number CGMCC No. 15528.

2. The uric acid-lowering composition according to claim 1, characterized in that, Includes the following components by weight: Sour cherry concentrate: 5 servings; Chrysanthemum powder: 2 parts; Asparagus powder: 3 portions; Small thistle powder: 2 portions; Vitamin C: 2 servings; Compound bacterial powder: 1 part; The total viable bacteria count of the compound bacterial powder is 20 billion CFU / g; The compound bacterial powder is composed of TSP05 and TSR332 with a live bacteria ratio of 1:1.7; TSP05 is Lactobacillus plantarum, with accession number CGMCC No. 16710; TSR332 is Lactobacillus reuteri, with accession number CGMCC No. 15528.

3. The use of the uric acid-lowering composition according to any one of claims 1 or 2 in the preparation of health products or pharmaceuticals with uric acid-lowering effects.

4. The application as described in claim 3, characterized in that, The health products or medicines mentioned are in the form of tablets, capsules, pills, powders, or oral liquids.

5. A powder with uric acid-lowering effect, characterized in that, The powder comprises the uric acid-lowering composition of claim 1 or 2.

6. The powder as described in claim 5, characterized in that, The powder also includes a sweetener.

7. An oral liquid with uric acid-lowering effect, characterized in that, The oral liquid comprises the uric acid-lowering composition of claim 1 or 2.

8. The oral liquid as described in claim 7, characterized in that, The oral liquid also includes sweeteners, preservatives, and drinking water.

9. The powder according to claim 6 or the oral liquid according to claim 8, characterized in that, The sweetener is at least one of the sweeteners acceptable in food.

10. The oral liquid as described in claim 8, characterized in that, The preservative is at least one of the preservatives acceptable for food.

Images